Manufacturers of up to 10 high-cost treatments including cell and gene therapies could be required to provide data to Medicaid on pricing, clinical benefit and the cost of production in an annual audit as part of an effort by the federal government to provide states with more tools to negotiate price concessions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?